Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined by new investors Columbus Venture Partners and British Patient Capital, alongside founding investor Advent Life Sciences and seed investor Epidarex Capital.

The investment will fuel the advancement of Curve's proprietary Microcycle® platform and its promising pipeline of novel therapeutics targeting challenging cancer mechanisms. The Microcycle® platform, known for its ability to discover biologically active molecules against historically difficult targets, has already produced first-in-class inhibitors with potential against a wide range of cancers.

Simon Kerry, CEO of Curve Therapeutics, highlighted the investment's role in expanding the team, advancing lead assets into clinical stages, and broadening the scope of their drug discovery platform. Chief Scientific Officer Professor Ali Tavassoli underscored the Microcycle platform's unique capacity to generate functional hits and leads, aiming to address unmet needs across various diseases.

Dr. Marie-Claire Peakman of Pfizer Ventures expressed enthusiasm for Curve's innovative approach to targeting significant yet previously intractable disease targets. With this funding, Curve is poised to progress its groundbreaking platform and therapeutic candidates, marking a crucial step forward in the fight against cancer.

Located at Southampton Science Park, Curve is expanding its research team and leveraging the vibrant life science ecosystem in Hampshire, benefiting from proximity to major biotech hubs in Oxford and London.